ArticleEClinicalMedicine2026
Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Antiretroviral therapy (ART) regimens without tenofovir have risks related to hepatitis B virus (HBV). As these regimens are being used more frequently, clinicians and policy makers would benefit from an accurate estimate of the risk of HBV outcomes following tenofovir cessation. Methods: We conducted a systematic review of HBV reactivation and infection in people with HIV who discontinue tenofovir. We searched Medline, Embase, Google Scholar, and the Cochrane database (1 January 2006-15 February 2026) for studies related to tenofovir cessation in people with HIV and (1) active HBV: positive HBV surface antigen (HBsAg); (2) resolved HBV: positive HBV core antibody (HBcAb) without HBsAg; and (3) susceptibility to HBV: negative HBsAg, HBcAb, and HBV surface antibody. We used a random effects model to calculate the pooled incidence rate of HBV reactivation (in resolved HBV) and new HBV infection (in those susceptible to HBV) after tenofovir cessation. We used multivariable meta-regression to compare pooled outcomes across subgroups. We used I Findings: Of 144 abstracts and articles, 53 underwent full-text review, and 22 unique observational studies were included. In eight studies of active HBV infection, only descriptive data could be retrieved without a meta-analysis: HBV DNA increase or hepatitis flares commonly occurred in most studies after tenofovir cessation or interruption. In six observational studies of resolved HBV infection with active surveillance of HBV serological markers after tenofovir cessation, pooled incidence of HBV reactivation was 3.79/100 person-years (95% CI 1.98-7.23; I Interpretation: In people with HIV, tenofovir-sparing ART is associated with risks related to HBV reactivation and infection. Higher quality prospective studies are needed in people with HIV who stop tenofovir. Funding: National Institutes of Health and Harvard University Center for AIDS Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.